IMMUTEP Ltd (IMMP)
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Immutep Limited
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 7.37M shares outstanding
AUImmutep Limited is a biotechnology enterprise focused on the exploration and advancement of medicinal candidates.
The company specializes in creating immunotherapeutic solutions for treating both cancerous conditions and autoimmune disorders.
Its primary investigational drug is eftilagimod alpha (referred to as efti or IMP321), a recombinant protein currently in a Phase IIb clinical trial, being assessed as a chemoimmunotherapy combination for metastatic breast cancer. Furthermore, Immutep is progressing several other programs: TACTI-002, which is undergoing Phase II clinical evaluation for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003, in a Phase IIb clinical study for HNSCC; INSIGHT-004 and INSIGHT-003, both in Phase I clinical trials for solid tumors; and INSIGHT-005, a Phase I/IIa clinical trial for solid tumors.
In addition to its oncology pipeline, the company's portfolio includes IMP761, an agonist targeting lymphocyte activation gene 3 for autoimmune diseases; IMP701, an antagonist antibody designed to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody aimed at eliminating T cells implicated in autoimmunity. Immutep Limited has established collaborative ventures with prominent organizations such as GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., the Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. Incorporated in 1987 and headquartered in Sydney, Australia, the company was formerly known as Prima BioMed Ltd, adopting the name Immutep Limited in November 2017.
Leadership
Marc Voigt
Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer & Executive Director
Frederic Triebel
Chief Scientific Officer & Executive Director
Stephan Winckels
Chief Medical Officer
Deanne Miller
Chief Operating Officer, General Counsel & Joint Company Secretary
Employees
41
Country
AU
Sector
Healthcare
Website
immutep.com
| Name | Shares | % | Source |
|---|---|---|---|
 Meyers Pete A. Director | 202.6K | 2.7% | FORM 4 |
 Mueller Christian Chief Development Officer | 188.7K | 2.6% | FORM 4 |
 Miller Deanne Diem Chief Operating Officer | 143.4K | 1.9% | FORM 4 |
BlackRock, Inc. | 37.1K | 0.5% | 13F |
 Boyce Elisabeth Amanda Director | 21.2K | 0.3% | FORM 4 |
Vanguard Personalized Indexing Management, LLC | 17.9K | 0.2% | 13F |
 Triebel Frederic Joseph Daniel Director | 8.5K | 0.1% | FORM 4 |
 Winckels Stephan Karel Gerard Chief Medical Officer | 4.6K | 0.1% | FORM 4 |
MARSHALL WACE, LLP | 4.4K | 0.1% | 13F |
TWO SIGMA INVESTMENTS, LP | 3.9K | 0.1% | 13F |
Insiders
- Meyers Pete A.Director
- Mueller ChristianChief Development Officer
- Miller Deanne DiemChief Operating Officer
- Boyce Elisabeth AmandaDirector
- Triebel Frederic Joseph DanielDirector
- Winckels Stephan Karel GerardChief Medical Officer
- Voigt MarcSee Remarks, Director
based on 7.37M shares outstanding
AU30d Avg
20.07K
60d Avg
20.47K
90d Avg
15.43K